UndisclosedDivestiture / carve-outHealthcare & Life SciencesCompleted
IMVIONIX buys US and Canadian rights to Novartis' Beovu
Georgia-based IMVIONIX acquired exclusive commercial rights in the US and Canada to Beovu (brolucizumab-dbll), approved for wet AMD and diabetic macular edema, from Novartis, and becomes its marketing authorization holder. The deal marks IMVIONIX's commercial launch; terms were not disclosed.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →